ImageneBio: Funding, Investors & Team (Oct 2026)
Diseases do not recognize borders; why should drug innovation? We are a team of scientists and physicians driven by a shared commitment: to fulfill unmet medical needs for patients worldwide by harnessing the most effective resources and efficient processes for drug development. We may take the brainchild of a scientist in one country to conduct proof of concept studies in another, and seamlessly transition to later clinical development globally. We coined our approach “Borderless Innovation.” Focused on immunology and inflammation, we are developing a new generation of drug candidates characterized by prolonged pharmacokinetic and pharmacodynamic effects as well as improved safety margins. This will potentially enable improved efficacy/safety profiles and dosing convenience. Leveraging cutting-edge technology, we have a rich pipeline consisting of four clinical-stage assets, targeting validated pathways, and multiple innovative preclinical candidates.
ImageneBio has raised $30.0M across 1 funding round on record, the most recent an undisclosed round of $30.0M announced in Apr 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ImageneBio Company Profile and Key Stats
Latest funding round on record: Apr 2026.
ImageneBio Funding Rounds
ImageneBio Founders and Leadership Team
No contact details are on record for this team yet.
ImageneBio Funding Compared to Other Biotechnology Startups
ImageneBio's latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ImageneBio in Biotechnology and San Diego
Companies Similar to ImageneBio
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
ImageneBio Funding FAQs
What does ImageneBio do?
Diseases do not recognize borders; why should drug innovation? We are a team of scientists and physicians driven by a shared commitment: to fulfill unmet medical needs for patients worldwide by harnessing the most effective resources and efficient processes for drug development. We may take the brainchild of a scientist in one country to conduct proof of concept studies in another, and seamlessly transition to later clinical development globally. We coined our approach “Borderless Innovation.” Focused on immunology and inflammation, we are developing a new generation of drug candidates characterized by prolonged pharmacokinetic and pharmacodynamic effects as well as improved safety margins. This will potentially enable improved efficacy/safety profiles and dosing convenience. Leveraging cutting-edge technology, we have a rich pipeline consisting of four clinical-stage assets, targeting validated pathways, and multiple innovative preclinical candidates.
How much funding has ImageneBio raised?
ImageneBio has raised $30.0M across 1 round on record. The most recent is an undisclosed round of $30.0M announced in Apr 2026.
When did ImageneBio last raise funding?
ImageneBio's most recent funding round on record is an undisclosed round of $30.0M, announced in Apr 2026.
Who founded ImageneBio?
FundedIQ lists Kristin Yarema (Founder) at ImageneBio.
Where is ImageneBio headquartered?
ImageneBio is based in San Diego, California, United States.
How many employees does ImageneBio have?
ImageneBio is in the 11-50 employee band.
How does ImageneBio's funding compare to other Biotechnology startups?
ImageneBio's latest round of $30.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ImageneBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImageneBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.